Genmab — Oktober 2018
-
http://www.evaluate.com/vantage/articles/data-insights/other-data/most-disputed-sales-outlooks-biopharma The most disputed sales outlooks in biopharma
-
There is still much uncertainty around Darzalex’s weighty 2024 forecast of $6bn, however; an unexplained price cut earlier this year shook investor confidence, and many analysts will be waiting to see how the drug fares in front-line settings to sharpen their sales predictions.
-
http://www.evaluate.com/vantage/articles/news/snippets/genmab-surges-maia-trial-opens-gates-us
Genmab surges as Maia trial opens gates to the US -
nåja - 906 er da bedre end et spark I nødderne
-
i første omgang bliver det spændende at se hvordan FDA tager imod ansøgningen
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind